about
Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South KoreaHuman isoprenoid synthase enzymes as therapeutic targetsLongitudinal Change in Trabecular Bone Score during and after Treatment of Osteoporosis in Postmenopausal Korean WomenEnhanced Osteogenic Differentiation in Zoledronate-Treated Osteoporotic Patients.Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism.Risk of atypical femoral fracture during and after bisphosphonate use.Mechanical competence of ovariectomy-induced compromised bone after single or combined treatment with high-frequency loading and bisphosphonates.A novel model of bisphosphonate-related osteonecrosis of the jaw in ratsNear IR fluorescent conjugated poly(ethylene glycol)bisphosphonate nanoparticles for in vivo bone targeting in a young mouse model.Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality.Bisphosphonate drug holiday: who, when and how long.Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.Skeletal Site-specific Effects of Zoledronate on in vivo Bone Remodeling and in vitro BMSCs Osteogenic ActivitySkeletal manifestations of treatment of breast cancer.Disentangling the emerging evidence around atypical fractures.Status of drug development for the prevention and treatment of osteoporosis.The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants.Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis.Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance.Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.Incidence of serious side effects with intravenous bisphosphonate: a clinical audit.Bisphosphonates, healthcare professionals and oral health.Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss.Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate.Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression.Intermittent Parathyroid Hormone After Prolonged Alendronate Treatment Induces Substantial New Bone Formation and Increases Bone Tissue Heterogeneity in Ovariectomized Rats.Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats.Bone Turnover Status: Classification Model and Clinical Implications.Engineering of a New Bisphosphonate Monomer and Nanoparticles of Narrow Size Distribution for Antibacterial ApplicationsBisphosphonates-induced Atypical Subtrochanteric Fracture Femur: A Case Report
P2860
Q26771713-FF5840B8-207E-418B-805E-EF06A38028A3Q26822639-46251060-E7FB-443C-8D5E-4D11CE352A3FQ33804839-C7C0CA0D-3995-40A1-9A01-6ED5254ACBB0Q33838933-E06C4271-D000-4BC2-9C08-66C29444A49EQ34734794-1270D3C0-52CF-4F81-8B82-2DAED8E12052Q35197628-83B0821C-CD3E-42DB-9C97-C3FF7EC87930Q35669754-40B49A48-2799-47EE-B438-3F9E4C546906Q35854092-E25B0414-56D8-48F0-9DB8-0EE22A5893E2Q36294187-4A114895-AE3D-4899-AC80-13A7C441116FQ36633388-E252FCF0-803D-4E42-B9E5-A334FFF2F8EFQ36999714-C583A24E-6349-4AAB-A4CA-153ED92BF473Q37522423-56D8D10F-E483-4CAB-8E20-15B1BC8519F9Q37615260-7AE39EF1-FDA3-4B79-BA28-C548F5439A03Q37630298-50E310D5-D131-4F5A-8769-BB86064F11A9Q37987492-A11313F9-A9C4-4883-BC49-4D18EB56B6A7Q38184588-D5D84C35-DACD-45D1-8DC0-6BAC233A1BD1Q38296795-1A051B6B-B1FE-4AA7-B1F5-99A179CDE222Q39271486-BDCA93DA-05BD-461D-B9E1-55FEC648B5A8Q40295687-00EEEF4C-E59E-43A6-B7F7-1201BBB8128BQ41477033-BC1973B4-FE3D-4D92-9C8B-6CC0CB23D396Q43573067-3F341C03-B03F-4370-BD56-48865719E65EQ43694921-319B845B-4ADE-45C7-A1B1-CCA3D42B4974Q45209793-1150B637-8FDF-4A54-B8CF-BC247D7CA9A0Q45367210-68F0672A-58F6-4A42-905D-9C6558CDBD27Q46153653-60107100-53FF-4EA1-A6CC-1250D9F236FBQ47958014-80C10956-1614-475A-8F89-643EAA984CA0Q50109392-2E8EFB40-BEB9-44FD-8BBF-3FE2BCC645B3Q50891008-EF1FACFD-349E-4434-BED9-7C2F3A5F5FFCQ51112327-04D1EE99-88C3-4210-9891-E7A7F564A9EEQ55002406-1DA6CAC9-A28B-4FE4-B13C-E1575F18ECB0Q56805984-80275256-C0B2-4A5D-BA78-FE62CA514EA3Q58568577-132D7868-C1DC-48A3-A8DF-B0677579927E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bisphosphonates for postmenopausal osteoporosis.
@en
Bisphosphonates for postmenopausal osteoporosis.
@nl
type
label
Bisphosphonates for postmenopausal osteoporosis.
@en
Bisphosphonates for postmenopausal osteoporosis.
@nl
prefLabel
Bisphosphonates for postmenopausal osteoporosis.
@en
Bisphosphonates for postmenopausal osteoporosis.
@nl
P2093
P1433
P1476
Bisphosphonates for postmenopausal osteoporosis.
@en
P2093
Ethel Siris
Jennifer S Walsh
Nelson B Watts
Richard Eastell
P356
10.1016/J.BONE.2011.02.011
P577
2011-02-22T00:00:00Z